- Investing Ideas
- U.S. Biotech Breakthroughs
U.S. Biotech Breakthroughs
Results
55
Biotech stocks worldwide which are expected to become profitable in the next 3 years.
55 companies
Travere Therapeutics
Market Cap: US$2.8b
A biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
TVTX
US$30.44
7D
11.7%
1Y
103.1%
Madrigal Pharmaceuticals
Market Cap: US$12.5b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$546.89
7D
7.1%
1Y
74.0%
Syndax Pharmaceuticals
Market Cap: US$2.2b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$25.15
7D
7.1%
1Y
123.6%
Precigen
Market Cap: US$1.4b
A discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.
PGEN
US$3.94
7D
7.4%
1Y
217.7%
Insmed
Market Cap: US$35.1b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$162.43
7D
11.8%
1Y
134.8%
Ardelyx
Market Cap: US$1.5b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.94
7D
8.4%
1Y
30.5%
Marker Therapeutics
Market Cap: US$22.0m
A clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States.
MRKR
US$1.32
7D
1.5%
1Y
32.0%
Rhythm Pharmaceuticals
Market Cap: US$5.9b
A commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally.
RYTM
US$86.29
7D
13.8%
1Y
83.8%
Cogent Biosciences
Market Cap: US$5.7b
A clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases.
COGT
US$35.21
7D
-2.5%
1Y
638.2%
ARS Pharmaceuticals
Market Cap: US$824.2m
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally.
SPRY
US$8.30
7D
2.9%
1Y
-35.2%
Lineage Cell Therapeutics
Market Cap: US$391.1m
A clinical-stage biotechnology company, developing cell replacement therapies to treat serious medical conditions in the United States and internationally.
LCTX
US$1.57
7D
5.4%
1Y
263.1%
Tenaya Therapeutics
Market Cap: US$150.7m
A clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
TNYA
US$0.69
7D
4.4%
1Y
39.3%
Capricor Therapeutics
Market Cap: US$1.8b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$32.11
7D
11.1%
1Y
254.4%
Aldeyra Therapeutics
Market Cap: US$99.9m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.66
7D
-6.2%
1Y
-12.2%
Pelthos Therapeutics
Market Cap: US$68.5m
A bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
PTHS
US$20.40
7D
-9.3%
1Y
49.6%
RenovoRx
Market Cap: US$44.2m
A clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment.
RNXT
US$0.98
7D
-13.3%
1Y
11.2%
CG Oncology
Market Cap: US$5.7b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$67.48
7D
4.4%
1Y
292.3%
AC Immune
Market Cap: US$273.8m
A clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding.
ACIU
US$2.76
7D
2.2%
1Y
66.3%
Arcutis Biotherapeutics
Market Cap: US$2.9b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$23.63
7D
11.4%
1Y
60.4%
Humacyte
Market Cap: US$142.6m
Engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.
HUMA
US$0.64
7D
-4.9%
1Y
-52.4%
Viridian Therapeutics
Market Cap: US$1.9b
Engages in discovering, developing, and commercializing treatments for serious and rare diseases.
VRDN
US$18.84
7D
-31.2%
1Y
57.1%
CollPlant Biotechnologies
Market Cap: US$7.6m
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally.
CLGN
US$0.53
7D
-15.2%
1Y
-78.5%
Invivyd
Market Cap: US$361.7m
Engages in the research, development, commercialization, and sale of antibody therapies for the prevention and treatment of viral infectious diseases in the United States.
IVVD
US$1.28
7D
-6.6%
1Y
146.2%
Vera Therapeutics
Market Cap: US$2.9b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$40.86
7D
5.1%
1Y
91.7%
Praxis Precision Medicines
Market Cap: US$8.6b
A clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States.
PRAX
US$310.38
7D
7.0%
1Y
850.6%
Unicycive Therapeutics
Market Cap: US$174.9m
A clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States.
UNCY
US$6.93
7D
8.5%
1Y
34.3%
Anavex Life Sciences
Market Cap: US$277.1m
Operates as a biopharmaceutical company.
AVXL
US$2.99
7D
6.0%
1Y
-63.5%
Benitec Biopharma
Market Cap: US$374.1m
A clinical-stage biotechnology company, focuses on the development of novel genetic medicines.
BNTC
US$10.92
7D
6.3%
1Y
-11.4%
Fennec Pharmaceuticals
Market Cap: US$221.3m
Operates as a commercial stage biopharmaceutical company in the United States.
FENC
US$6.42
7D
8.6%
1Y
22.3%
Arcellx
Market Cap: US$6.7b
Together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.
ACLX
US$114.77
7D
0.2%
1Y
95.9%
Day One Biopharmaceuticals
Market Cap: US$2.2b
A commercial-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for childhood and adult diseases with equal intensity in the United States.
DAWN
US$21.45
7D
0.2%
1Y
197.1%
Prelude Therapeutics
Market Cap: US$285.6m
A clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.
PRLD
US$3.46
7D
13.4%
1Y
412.6%
Savara
Market Cap: US$1.4b
A clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States.
SVRA
US$5.56
7D
8.2%
1Y
95.1%
Ionis Pharmaceuticals
Market Cap: US$12.4b
A commercial-stage biotechnology company, provides RNA-targeted medicines in the United States.
IONS
US$74.79
7D
3.7%
1Y
176.1%
Fortress Biotech
Market Cap: US$80.7m
A biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products.
FBIO
US$2.60
7D
-5.8%
1Y
71.1%
Mirum Pharmaceuticals
Market Cap: US$5.7b
A biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases.
MIRM
US$94.17
7D
6.5%
1Y
124.1%